Capecitabine
- Strength
- 500 mg/1
- Form
- Tablet, Film Coated
- Class
- Nucleoside Metabolic Inhibitor
Novadoz Pharmaceuticals LLC
Capecitabine
Listed by Sun Pharmaceutical Industries, Inc.
- Strength
- 150 mg/1
- Form
- Tablet, Film Coated
- Route
- Oral
- Class
- Nucleoside Metabolic Inhibitor
What it contains
- Capecitabine 150 mg/1
FDA record
| Dosage form | Tablet, Film Coated |
|---|---|
| Route | Oral |
| Drug class | Nucleoside Metabolic Inhibitor |
| Approval route | ANDA — approved generic |
| NDC code | 62756-238 |
| FDA application | ANDA204668 |
| RxNorm concept | 200327 |
| Package sizes listed | 3 |
| Marketed since | September 2019 |
Other products containing Capecitabine
See allSame active ingredient, different manufacturer, strength or form. Products matching on both ingredient and strength are usually interchangeable — but confirm before switching, especially with modified-release forms.
CAPECITABINE
- Strength
- 150 mg/1
- Form
- Tablet, Film Coated
- Class
- Nucleoside Metabolic Inhibitor
Accord Healthcare Inc.
Capecitabine
- Strength
- 500 mg/1
- Form
- Tablet, Film Coated
- Class
- Nucleoside Metabolic Inhibitor
Teyro Labs Private Limited
Capecitabine
- Strength
- 150 mg/1
- Form
- Tablet, Film Coated
- Class
- Nucleoside Metabolic Inhibitor
Teva Pharmaceuticals USA, Inc.
Capecitabine
- Strength
- 500 mg/1
- Form
- Tablet, Film Coated
- Class
- Nucleoside Metabolic Inhibitor
Golden State Medical Supply, Inc.
Capecitabine
- Strength
- 500 mg/1
- Form
- Tablet, Film Coated
- Class
- Nucleoside Metabolic Inhibitor
American Health Packaging
Capecitabine
- Strength
- 150 mg/1
- Form
- Tablet, Film Coated
- Class
- Nucleoside Metabolic Inhibitor
Ascend Laboratories, LLC
Capecitabine
- Strength
- 500 mg/1
- Form
- Tablet, Film Coated
- Class
- Nucleoside Metabolic Inhibitor
Ascend Laboratories, LLC
Information only, not medical advice. Nothing on this page indicates that a medication is safe or suitable for you. Speak to a prescriber or pharmacist before starting, stopping or switching any medicine.